Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00 at Piper Sandler

Compass Therapeutics (NASDAQ:CMPX) had its price objective lifted by analysts at Piper Sandler from $4.00 to $6.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s target price would suggest a potential upside of 179.72% from the company’s current price.

Other research analysts also recently issued reports about the company. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research note on Monday, June 1st. HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $11.77.

Compass Therapeutics Trading Up 7.8%

NASDAQ CMPX traded up $0.15 during trading hours on Friday, reaching $2.15. The company’s stock had a trading volume of 2,131,049 shares, compared to its average volume of 4,718,508. The business has a 50-day simple moving average of $2.10 and a 200 day simple moving average of $3.88. Compass Therapeutics has a 52 week low of $1.61 and a 52 week high of $6.88. The stock has a market cap of $386.29 million, a PE ratio of -5.21 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities analysts predict that Compass Therapeutics will post -0.42 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Simplicity Wealth LLC bought a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $80,000. Bank of New York Mellon Corp bought a new position in shares of Compass Therapeutics in the second quarter valued at approximately $769,000. State of Wyoming bought a new position in shares of Compass Therapeutics in the second quarter valued at approximately $31,000. GSA Capital Partners LLP acquired a new position in shares of Compass Therapeutics during the second quarter valued at approximately $154,000. Finally, Walleye Trading LLC acquired a new position in shares of Compass Therapeutics during the second quarter valued at approximately $55,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.